Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Breast
06:46

Xth Eurasian Hematology-Oncology Congress

Systemic Therapy in Early HER2+ Breast Cancer: More Benefit w/Neoadjuvant Trastuzumab/Pertuzumab/Docetaxel Therapy, Adjuvant Trastuzumab Improves DFS and OS

FEATURING Cagatay Arslan
  • 137 views
  • December 4, 2019
23:24

Xth Eurasian Hematology-Oncology Congress

Systemic Adjuvant Therapy in Early HER2+ Breast Cancer: Escalating w/New HER2 Targeted Tx (Neratinib, Pertuzumab, T-DMI1), and When to De-Escalate?

FEATURING Cagatay Arslan
  • 174 views
  • December 4, 2019
  • 1
09:24

Xth Eurasian Hematology-Oncology Congress

Evolving Approaches in Systemic Therapy for TNBC in Adjuvant Setting: Negative Impact if Initiation of Chemotherapy is Delayed

FEATURING Ozlem Er
  • 319 views
  • December 4, 2019
  • 1
23:29

Xth Eurasian Hematology-Oncology Congress

Systemic Therapy for TNBC in Neoadjuvant Setting: Initial Treatment for Stage II/III, Chemo as a Potential SoC and Preferred Treatment Strategy, Checkpoint Inhibitors Under Clinical Investigation

FEATURING Ozlem Er
  • 240 views
  • December 4, 2019
  • 2
32:43

Xth Eurasian Hematology-Oncology Congress

Adjuvant Therapy in ER+ / HER2- Early Breast Cancer: Is Chemotherapy an Optimal Treatment Option?

FEATURING Mehmet Ali Kaplan
  • 72 views
  • December 4, 2019
15:29

Xth Eurasian Hematology-Oncology Congress

Optimizing Therapy for ER+ Metastatic Breast Cancer: CDK 4/6 + Endocrine Therapy as 1st Line, Everolimus-Exemestane PI3K as a Reasonable Options for Mutant Patients

FEATURING Sema Sezgin Göksu
  • 101 views
  • December 4, 2019
10:36

Xth Eurasian Hematology-Oncology Congress

Overcoming Resistance in HER2+ Metastatic Breast Cancer: Single Anti-HER2 and Dual HER2 Blockade Resistance

FEATURING Sernaz Uzunoğlu
  • 58 views
  • December 4, 2019
13:37

Xth Eurasian Hematology-Oncology Congress

Overcoming Resistance in HER2+ Metastatic Breast Cancer: Inhibiting HER2 Signalling More Effectively w/ Dual Blockade, Antibodies, Bispecific Antibodies, Novel TKIs, Anti-HER2 + CPis, CDK4-6 or PI3K/AKT/mTOR

FEATURING Sernaz Uzunoğlu
  • 97 views
  • December 4, 2019
18:51

Xth Eurasian Hematology-Oncology Congress

PARPi as the Emerging Treatment Strategy in BRCA+ Metastatic TNBC: Improvement in PFS in Platinum Naive /Sensitive Disease

FEATURING Omer Dizdar
  • 63 views
  • December 4, 2019